Sort
25,944 grants matching “neurodegeneration”
Discovering How Cu(II)/Zn(II) Uptake by the Prion Protein Controls Structure, Function and Neurotoxicity
$342,635Glenn L Millhauser · University Of California Santa Cruz · R35 · FY2023 · GM
Discovering How Cu(II)/Zn(II) Uptake by the Prion Protein Controls Structure, Function and Neurotoxicity
$342,635Glenn L Millhauser · University Of California Santa Cruz · R35 · FY2022 · GM
Discovering How Cu(II)/Zn(II) Uptake by the Prion Protein Controls Structure, Function and Neurotoxicity
$342,635Glenn L Millhauser · University Of California Santa Cruz · R35 · FY2020 · GM
Cognitive Neuroplasticity and Recovery of Function Following Brain Damage
$342,622Jordan Grafman · Neurological Disorders And Stroke · Z01 · FY2007 · NS
(PQ9) Mitigation of chemotherapy induced peripheral neuropathy
$342,604David A. Gewirtz · Virginia Commonwealth University · R01 · FY2020 · CA
Genetic Control of Purkinje Cell Degeneration
$342,563Susan L Ackerman · Jackson Laboratory · R01 · FY2009 · NS
The Regulation of Synaptic Connectivity and Homeostasis by Huntingtin
$342,543Cagla Eroglu · Duke University · R01 · FY2016 · NS
Role of perivascular aquaporin-4 polarization in post-traumatic neurodegeneration
$342,469Jeffrey J Iliff · Oregon Health & Science University · R01 · FY2017 · NS
RNA-binding RNA Polymerase II CTD-associated Proteins
$342,468Jeffry L. Corden · Johns Hopkins University · R01 · FY2009 · GM
Ataxin-2 as a genetic risk factor for ALS: New insights into neurodegeneration
$342,457Nancy M Bonini · University Of Pennsylvania · R01 · FY2011 · NS
Structure and function of protein kinase/PP2A complexes
$342,452Brian E Wadzinski · Vanderbilt University · R01 · FY2010 · GM
THE FADD/CASPASE-8 PATHWAY AS A MEDIATOR OF LRRK2 NEUROTOXICITY
$342,360William T Dauer · Columbia University Health Sciences · P50 · FY2010 · NS
Molecular Genetic Analysis of TORC1 and TORC2 Signaling in Neuronal Maintenance
$342,344Bingwei Lu · Stanford University · R01 · FY2021 · NS
Extracellular alpha-synuclein in Parkinson's Disease
$342,344Pamela J McLean · Mayo Clinic Jacksonville · R01 · FY2015 · NS
Role of LRRK2 in idiopathic Parkinson's disease
$342,344J Timothy Greenamyre · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · NS
Role of LRRK2 in idiopathic Parkinson's disease
$342,344J Timothy Greenamyre · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · NS
Molecular Genetic Analysis of TORC1 and TORC2 Signaling in Neuronal Maintenance
$342,344Bingwei Lu · Stanford University · R01 · FY2019 · NS
Role of LRRK2 in idiopathic Parkinson's disease
$342,344J Timothy Greenamyre · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · NS
Role of LRRK2 in idiopathic Parkinson's disease
$342,344J Timothy Greenamyre · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · NS
Molecular Genetic Analysis of TORC1 and TORC2 Signaling in Neuronal Maintenance
$342,344Bingwei Lu · Stanford University · R01 · FY2023 · NS
Molecular Genetic Analysis of TORC1 and TORC2 Signaling in Neuronal Maintenance
$342,344Bingwei Lu · Stanford University · R01 · FY2020 · NS
Molecular Genetic Analysis of TORC1 and TORC2 Signaling in Neuronal Maintenance
$342,344Bingwei Lu · Stanford University · R01 · FY2022 · NS
Extracellular alpha-synuclein in Parkinson's Disease
$342,344Pamela J McLean · Mayo Clinic Jacksonville · R01 · FY2012 · NS
Cell cycle events: outcomes measures in Alzheimer models
$342,340Karl Herrup · Rutgers, The State Univ Of N.J. · R01 · FY2006 · AG
Characterization of purified myocilin: glaucoma as a protein misfolding disease
$342,328Raquel L Lieberman · Georgia Institute Of Technology · R01 · FY2011 · EY